PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
8935.00 - 9125.00
6347.00 - 10045.00
380.0K / 335.9K (Avg.)
23.15 | 391.09
Helps investors judge whether earnings growth is driven by sustainable operations or temporary factors. Consistent, organic income expansion can justify a higher intrinsic value for patient, long-term investors.
5.21%
Growth of 5.21% versus flat Medical - Pharmaceuticals revenue. Walter Schloss would verify growth quality.
4.46%
Cost growth exceeding 1.5x Medical - Pharmaceuticals median of 1.59%. Jim Chanos would check for structural cost disadvantages.
8.31%
Growth of 8.31% versus flat Medical - Pharmaceuticals gross profit. Walter Schloss would verify quality.
2.95%
Margin change of 2.95% versus flat Medical - Pharmaceuticals margins. Walter Schloss would verify quality.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
10.78%
Other expenses change of 10.78% versus flat Medical - Pharmaceuticals costs. Walter Schloss would verify efficiency.
3.60%
Operating expenses growth below 50% of Medical - Pharmaceuticals median of 8.79%. Joel Greenblatt would investigate efficiency.
4.32%
Total costs growth 50-90% of Medical - Pharmaceuticals median of 6.44%. Mohnish Pabrai would examine discipline.
4.76%
Interest expense change of 4.76% versus flat Medical - Pharmaceuticals costs. Walter Schloss would verify control.
9.72%
D&A growth exceeding 1.5x Medical - Pharmaceuticals median of 0.52%. Jim Chanos would check for overinvestment.
25.60%
EBITDA growth while Medical - Pharmaceuticals declines. Peter Lynch would examine advantages.
19.38%
Margin change of 19.38% versus flat Medical - Pharmaceuticals. Walter Schloss would verify quality.
27.07%
Operating income growth while Medical - Pharmaceuticals declines. Peter Lynch would examine advantages.
20.78%
Margin change of 20.78% versus flat Medical - Pharmaceuticals. Walter Schloss would verify quality.
12.17%
Other expenses change of 12.17% versus flat Medical - Pharmaceuticals. Walter Schloss would verify control.
25.67%
Pre-tax income growth while Medical - Pharmaceuticals declines. Peter Lynch would examine advantages.
19.45%
Margin change of 19.45% versus flat Medical - Pharmaceuticals. Walter Schloss would verify quality.
-5.71%
Tax expense reduction while Medical - Pharmaceuticals median is 0.00%. Seth Klarman would investigate advantages.
40.70%
Net income growth while Medical - Pharmaceuticals declines. Peter Lynch would examine advantages.
33.73%
Margin change of 33.73% versus flat Medical - Pharmaceuticals. Walter Schloss would verify quality.
40.71%
EPS growth while Medical - Pharmaceuticals declines. Peter Lynch would examine advantages.
40.71%
Diluted EPS growth while Medical - Pharmaceuticals declines. Peter Lynch would examine advantages.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.